VCYT VERACYTE, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: development and commercialization of genomic and molecular diagnostic tests for oncology and other indications
• • Emphasis on regulatory adaptations for IVDR/UKNI in Northern Ireland, and new Swiss IvDO aligning with IVDR from 2022
• • Increased complexity in billing, coding changes including CPT codes 81546 (Afirma), 81542 (Decipher Prostate), 0016M (Decipher Bladder) affecting revenue collection
• • Competition intensifying in genomics and MRD testing, notable competitors include Exact Sciences, Natera, Myriad, Guardant, affecting market positioning
• • Regulatory compliance and quality system updates with FDA's revised QMSR due Feb 2026 impacting manufacturing and post-market obligations

Risk Factors

• • Regulatory risk from Protecting Access to Medicare Act of 2014 (PAMA) may reduce test reimbursement rates, negatively impacting revenues and margins
• • Geopolitical risk from Middle East conflicts potentially disrupting Israel business and employees acquired in C2i Acquisition
• • Supply chain vulnerability from reliance on single-source reagents and consumables affecting test volume and reporting timelines
• • Competitive risk of payer cost containment tactics including prior authorization and lab benefit managers limiting test utilization
• • Financial risk from revenue concentration with Medicare and UnitedHealthcare representing 47% and 14% of total revenue respectively in 2025

Management Discussion & Analysis

• • Revenue not explicitly stated; net income $66.4M in 2025 vs $24.1M in 2024, showing significant profitability improvement
• • Operating margin details not provided; net income growth from $24.1M (2024) to $66.4M (2025) indicates margin improvement
• • Segment performance data not disclosed, no best or worst segment specified
• • Cash and equivalents $412.9M as of Dec 31, 2025, increased by $123.4M in 2025; operating cash flow $136.3M in 2025 vs $75.1M in 2024; no dividend or buyback disclosed
• • Management highlights potential reversal of deferred tax asset valuation allowance; risks include financing dependency if cash flow declines; capex approx. $9.7M in 2025

What are the latest VCYT SEC filings in 2026?

VERACYTE, INC. (VCYT) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did VCYT file its most recent 10-K annual report?

VERACYTE, INC. (VCYT) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view VCYT 10-Q quarterly reports?

VERACYTE, INC. (VCYT)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every VCYT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has VCYT filed recently?

VERACYTE, INC. (VCYT)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find VCYT insider trading activity (Form 4)?

SignalX aggregates every VCYT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does VCYT file with the SEC?

VERACYTE, INC. (VCYT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new VCYT filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for VERACYTE, INC. (VCYT).

What is VCYT's SEC CIK number?

VERACYTE, INC. (VCYT)'s SEC CIK (Central Index Key) number is 1384101. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1384101 to look up all VCYT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find VCYT return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from VERACYTE, INC. (VCYT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.